Stock analysis, price data, and AI-powered insights for Dexcom (DXCM).
Dexcom operates in the Healthcare sector and is a constituent of the S&P 500 index. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for DXCM.
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). DXCM Stock Intelligence Report. [stoxpulse.com/stocks/dxcm]
Disclaimer: The information on this page about Dexcom (DXCM) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Dexcom.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
Earnings beat by 17%
Mar 31
Coleman sold 5K shares
Jun 4
Coleman sold 5K shares
Jun 3
FDA Clears First Over-The-Counter Continuous Gluco...
2d ago
DexCom Expands Beyond CGMs With CONNECT Results AI...
2d ago
StoxPulse AI results for DXCM: Pulse Score 52.5/100. Primary sentiment trends from 11 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$29.08B
P/E Ratio
35.2
EPS
$0.51
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Jun 25
+6.8%
Sep 25
+5.3%
Dec 25
-32.1%
Mar 26
+17.0%
Beat estimates 3 of 4 quarters (75%)
Sector
Healthcare
Industry
Health Care Equipment
FDA Clears First Over-The-Counter Continuous Glucose Monitor For Children
DexCom Expands Beyond CGMs With CONNECT Results AI Apps And Nutrisense Deal
3 Reasons Investors Love DexCom (DXCM)
TD Cowen Maintains Buy on DexCom, Raises Price Target to $95
1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm
Mizuho Maintains Outperform on DexCom, Raises Price Target to $85
DexCom Reports Positive CONNECT Data for Non-Insulin Diabetes
Clinical Wins Boost Dexcom Growth Story In Type 2 Diabetes